Page last updated: 2024-12-10
bms 180742
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
BMS 180742: amino acid sequence given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 3083292 |
MeSH ID | M0195299 |
Synonyms (5)
Synonym |
---|
succinyl-phe-glu-pro-ile-pro-glu-glu-tyr-cyclohexylalanine-gln |
l-glutamine, n2-(n-(n-(n-(n-(1-(n-(1-(n-(n-(3-carboxy-1-oxopropyl)-l-phenylalanyl)-l-alpha-glutamyl)-l-prolyl)-l-isoleucyl)-l-prolyl)-l-alpha-glutamyl)-l-alpha-glutamyl)-l-tyrosyl)-3-cyclohexyl-l-alanyl)- |
138828-04-3 |
bms 180742 |
DTXSID10160801 |
Research Excerpts
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" Dose-response relationships were determined with a thrombin active site inhibitor, N-methyl (GYKI 14,766); a thrombin exosite inhibitor, succinyl-Phe-Glu-Pro-Ile-Pro-Glu-Glu-Tyr-cyclohexylalanine-Gln (BMS 180,742); and heparin." | ( Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding. Heran, CL; Michel, IM; Ogletree, ML; Schumacher, WA; Seiler, SM; Steinbacher, TE, 1993) | 0.29 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 5 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.66
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.66) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |